Research Article
Policosanol Attenuates Statin-Induced Increases in Serum Proprotein Convertase Subtilisin/Kexin Type 9 When Combined with Atorvastatin
Table 2
Effects of policosanol on plasma proprotein convertase subtilisin/kexin type 9, uric acid, and lipid parameters in two protocols.
| Variable | I. Patients with atherosclerosis | II. Healthy volunteers | Atorvastatin () | Policosanol + atorvastatin () | Control () | Policosanol () | Baseline | 8 weeks | Baseline | 8 weeks | Baseline | 12 weeks | Baseline | 12 weeks |
| PCSK9 (ng/ml; mean ± SD) | 256 ± 84 | 357 ± 101$ | 264 ± 60 | 310 ± 86 | 274 ± 77 | 255 ± 54 | 289 ± 71 | 235 ± 46# | Uric acid (mol/L; mean ± SD) | 360 ± 70 | 377 ± 67 | 332 ± 66 | 320 ± 89 | 323 ± 77 | 322 ± 76 | 344 ± 115 | 288 ± 98* | Total cholesterol (mmol/L; mean ± SD) | 4.91 ± 0.91 | 3.61 ± 0.85$ | 4.75 ± 0.78 | 3.35 ± 0.66$ | 5.23 ± 0.54 | 5.10 ± 0.94 | 4.94 ± 0.77 | 4.72 ± 1.00 | Triglycerides (mmol/L; mean ± SD) | 1.95 ± 0.78 | 1.46 ± 0.62$ | 1.77 ± 1.20 | 1.31 ± 0.83* | 1.59 ± 0.96 | 1.41 ± 0.76 | 1.12 ± 0.47 | 0.94 ± 0.15 | HDL-C (mmol/L; mean ± SD) | 1.04 ± 0.23 | 0.98 ± 0.26 | 1.16 ± 0.27 | 1.12 ± 0.21 | 1.31 ± 0.42 | 1.35 ± 0.40 | 1.61 ± 0.46 | 1.54 ± 0.40 | LDL-C (mmol/L; mean ± SD) | 3.12 ± 0.89 | 1.97 ± 0.78$ | 2.98 ± 0.75 | 1.87 ± 0.54$ | 2.94 ± 0.50 | 3.16 ± 0.89 | 2.57 ± 0.67 | 2.78 ± 0.83 | Apoprotein AI (g/L; mean ± SD) | 1.61 ± 0.31 | 1.35 ± 0.34 | 1.46 ± 0.27 | 1.31 ± 0.34 | 1.71 ± 0.36 | 1.67 ± 0.32 | 1.87 ± 0.40 | 1.71 ± 0.26 | Apoprotein B (g/L; mean ± SD) | 1.29 ± 0.38 | 0.75 ± 0.26$ | 1.08 ± 0.23 | 0.65 ± 0.22$ | 0.83 ± 0.12 | 0.88 ± 0.20 | 0.70 ± 0.11 | 0.76 ± 0.15 | Free fatty acid (mmol/L; mean ± SD) | 0.50 ± 0.12 | 0.62 ± 0.20 | 0.36 ± 0.13 | 0.32 ± 0.25 | 0.39 ± 0.14 | 0.38 ± 0.13 | 0.49 ± 0.42 | 0.45 ± 0.16 |
|
|
< 0.05 versus baseline; $ < 0.01 versus baseline; # = 0.069 versus baseline. PCSK9, proprotein convertase subtilisin/kexin type 9; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
|